Plain-English translation of NCT07607964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called for people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) — two serious autoimmune conditions that cause the body's immune system to attack itself. Researchers want to understand how the medication moves through your body, how it works, and whether it is safe. About 30 people will participate, with some receiving the treatment as an intravenous infusion and others as a subcutaneous injection.
Current treatments don't work well enough for everyone with lupus and rheumatoid arthritis, and some people don't respond to existing medications. This trial is exploring whether this new treatment could help people whose disease isn't controlled by other available options.
You likely qualify if…
You likely don't qualify if…
You will participate in the trial for approximately 14 months total (about 2 months of screening, then a 1-day treatment visit, followed by 52 weeks of follow-up visits). During the screening period, you'll have blood tests and medical assessments to make sure you're eligible. On the treatment day, you'll receive a single dose of the medication either as an intravenous infusion or as a subcutaneous injection. After that, you'll attend regular clinic visits for blood work, physical exams, side effect checks, and questionnaires to see how the treatment is working and ensure you're safe. There will be more frequent visits early on, with the visits spaced out over time.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States